A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer
Metrics: PDF 216 views | Full Text 1251 views | ?
Sachi Fukui-Kawaura1, Takashi Kawahara2, Yushi Araki1, Reona Nishimura1, Koichi Uemura1, Kazuhiro Namura1, Nobuhiko Mizuno1, Masahiro Yao3, Hiroji Uemura2 and Ichiro Ikeda1
1 Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan
2 Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
3 Department of Urology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
Keywords: AST; ALT; De Ritis; high risk NMIBC
Received: October 26, 2020 Accepted: March 24, 2021 Published: April 27, 2021
Background: High-risk non-muscle invasive bladder cancer (NMIBC) is thought to be associated with a higher risk of recurrence and progression. A recent study revealed that a high De Ritis ratio was a risk factor in some solid malignancies. This study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC.
Materials and Methods: A total of 138 patients who were initially diagnosed with high-risk NMIBC between January 2012 to December 2016 were enrolled in this study. The criteria for the high-risk classification followed the EAU guidelines. The recurrence-free and progression-free survival of the higher and lower De Ritis ratio groups were compared. The cut-off value of the De Ritis ratio was set at 1.35, based on a receiver operator curve analysis.
Results: The median observation period was 50.3 months. Among these patients, 32 (23.1%) patients developed recurrent disease and 15 (10.9%) patients showed progression. A multivariate analysis revealed that non-BCG treatment was an independent risk factor for recurrence, and a higher De Ritis ratio was an independent risk factor for cancer progression.
Conclusions: The De Ritis ratio might be a risk factor for progression in high-risk NMIBC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.